AIDS Therapies

Researchers Warn Against Amprenavir Combinations In HIV/MAC Coinfected Patients

Published in AIDS Weekly, March 19th, 2001

by Michael Greer, staff medical writer -- Neither rifabutin nor rifampin should be used to prevent Mycobacterium avium complex (MAC) in HIV patients treated with the protease inhibitor amprenavir, researchers warn.

R.E. Polk and colleagues at Virginia Commonwealth University studied the interactions between amprenavir and common prophylactic MAC treatments.

They found that amprenavir can prevent the clearance of rifabutin, forcing almost half of the patients studied to discontinue therapy. Conversely, rifampin was found to hasten amprenavir clearance.

Concomitant administration of amprenavir and rifabutin increased...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-03-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry